3 withdrawn. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Withdrawn 3 |
| Phase 2 | 2 | Withdrawn 2 |
Follow PTSD: new trials by email Literature Review of PTSD trials Research Report on PTSD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM) Fluoroethylnormemantine (FENM) - PTSD, Alzheimer Disease | Phase 1 | Withdrawn | ReST Therapeutics | 2024-05-02 | 2024-05-03 | |
| Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD Ketamine Hydrochloride - PTSD | Phase 1 / Phase 2 | Withdrawn | University of New Mexico | 2023-12-31 | 2024-03-12 | |
| Mindful Yoga Therapy as an Adjunctive Treatment for PTSD Among OEF/OIF Veterans Mindful Yoga Therapy, Wait-list Control - PTSD | Phase 1 / Phase 2 | Withdrawn | VA Connecticut Healthcare System | 2013-04-01 | 2014-12-19 |
Stress Disorders, Post-Traumatic (3) · Alzheimer Disease (1) · Brain Diseases (1) · Depressive Disorder, Major (1) · Depressive Disorder, Treatment-Resistant (1)
Mental Disorders (3) · Stress Disorders, Traumatic (3) · Trauma and Stressor Related Disorders (3) · Central Nervous System Diseases (1) · Dementia (1) · Depressive Disorder (1) · Mood Disorders (1) · Nervous System Diseases (1) · Neurocognitive Disorders (1) · Neurodegenerative Diseases (1) · Tauopathies (1)
Ketamine (1) · fluoroethylnormemantine (1)
ReST Therapeutics (1) · University of New Mexico (1) · VA Connecticut Healthcare System (1)
United States (2) · Belgium (1)
Alicia Heapy, Ph.D. (1) · Snehal Bhatt, MD (1)